Tarsus Pharmaceuticals, Inc.
TARS
株式のランク
#4590
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
株価
$71.12
最終同期: 2026-10-20
時価総額
$3.33B
変化（1日）
2.33%
変化（1年）
0.42%
国
US
取引 Tarsus Pharmaceuticals, Inc. (TARS)
カテゴリー
Healthcare
Tarsus Pharmaceuticals, Inc.（TARS）の発行済株式数
June 2026 時点の発行済株式数 43.39M
Tarsus Pharmaceuticals, Inc. の最新の財務報告および株価によると、現在の発行済株式数は 43.39M です。December 2023 の終わりには、同社は 29.38M 株の発行済株式 を有していました。発行済株式数は、通常、株式分割や自社株買いによって影響を受けます。
Tarsus Pharmaceuticals, Inc.（TARS）の発行済株式数の履歴（2018 ～ 2026）
各年末時点の発行済株式数
| 年 | 発行済株式数 | 変化 |
|---|---|---|
| 2026 (TTM) | 43.39M | 15.39% |
| 2024 | 37.60M | 27.98% |
| 2023 | 29.38M | 19.35% |
| 2022 | 24.62M | 19.78% |
| 2021 | 20.55M | 1.14% |
| 2020 | 20.32M | 4.17% |
| 2019 | 19.51M | 355.26% |
| 2018 | 4.29M | 0.00% |
類似企業や競合他社の発行済株式数
| 企業 | 発行済株式数 | 差 | 国 |
|---|---|---|---|
| 253.90M | 485.11% |
US
|
|
| 396.00M | 812.58% |
US
|
|
| 478.91M | 1,003.65% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | 43.31% |
NL
|
